Contact: [email protected]
* Studie on hold of geen beschikbare plaatsen
| Title | Characteristics | Line | Study information |
|---|---|---|---|
| CAMBRIA-1 | HER2- / HR+ | Adjuvant | Camizestrant vs. SOC ET; 2-5y on adj ET |
| TACTIVE-U/C4891024* | HER2- / ER+ | 1-3L | ARV-471 oral Proteolysis Targeting Chimera; prior CDK4/6 required |
| Opera-01* | HER2- / ER+ | 2-3L | OP-1250 Palazestrant vs. SOC; prior CDK4/6 required; no prior chemo |
| ELECTRA/ELA-0121 | HER2- / ER+ | 2-3L | Elacestrant + Abemaciclib |
| VIKTORIA-1/CELC-G-301 | HER2- / ER+ | 2-3L | Gedatolisib PI3K inhibitor + Palbociclib + Fulvestrant vs. Gedatolisib + Fulvestrant; no prior chemo |
| Capitello292 | HER2-/HR+ | 1(-2)L | Capivasertib + CDK4/6 inhibitor + Fulvestrant vs CDK4/6 inhibitor + Fulvestrant |
| TACTIVE-K/ C4891026 | HER2-/HR+ | ≥2L | ARV-471 (vepdegestrant) + PF-07220060 |
| CAMBRIA-2 | HER2-/HR+ | Adjuvant | Camizestrant (AZD9833) vs Standard ET (AI or tamoxifen) |
| JZP598-303 | HER2+ | 3-5L | Zanidatamab + Chemotherapy (eribulin, gemcitabine, vinorelbine, or capecitabine) vs Trastuzumab + Chemotherapy (eribulin, gemcitabine, vinorelbine, or capecitabine) |